Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reiterated at FBR & Co
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by investment analysts at FBR & Co in a research note issued to investors on Thursday.
Several other research firms have also recently weighed in on ALNY. Morgan Stanley set a $93.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $65.00 target price (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 10th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Tuesday, August 9th. Cowen and Company reiterated a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 5th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $113.62.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 5.07% during trading on Thursday, hitting $69.79. The stock had a trading volume of 501,100 shares. The stock’s market cap is $5.98 billion. The stock’s 50-day moving average price is $71.71 and its 200 day moving average price is $64.60. Alnylam Pharmaceuticals has a one year low of $49.96 and a one year high of $110.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/alnylam-pharmaceuticals-alny-buy-rating-reiterated-at-fbr-co.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same period in the prior year, the company earned ($0.85) earnings per share. The business’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.64) EPS for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.00% of the stock is currently owned by corporate insiders.
Several hedge funds recently modified their holdings of ALNY. IBM Retirement Fund raised its stake in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 76 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its stake in shares of Alnylam Pharmaceuticals by 3.1% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 5,284 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 160 shares in the last quarter. Aviva PLC raised its stake in shares of Alnylam Pharmaceuticals by 0.6% in the first quarter. Aviva PLC now owns 36,627 shares of the biopharmaceutical company’s stock worth $2,299,000 after buying an additional 207 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 38,162 shares of the biopharmaceutical company’s stock worth $2,395,000 after buying an additional 450 shares in the last quarter. Finally, Credit Agricole S A raised its stake in shares of Alnylam Pharmaceuticals by 11.6% in the first quarter. Credit Agricole S A now owns 12,182 shares of the biopharmaceutical company’s stock worth $765,000 after buying an additional 1,270 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.